Dendritic cells transfected with a polyepitope DNA construct stimulate an antitumor cytotoxic response in various tumors

Kurilin,Vasily; Kulikova,Ekaterina; Shevchenko,Julia; Lopatnikova,Julia; Obleukhova,Irina; Khantakova,Julia; Maksyutov,Amir; Kuznetsova,Maria; Khristin,Alexander; Kiryshina,Natalya; Kozlov,Vadim; Sidorov,Sergey; Sokolov,Andrey; Vitsin,Alexander; Shiku,Hiroshi; Sennikov,Sergey

doi:10.3892/mco.2022.2588

Dendritic cells transfected with a polyepitope DNA construct stimulate an antitumor cytotoxic response in various tumors

Authors:
- Vasily Kurilin
- Ekaterina Kulikova
- Julia Shevchenko
- Julia Lopatnikova
- Irina Obleukhova
- Julia Khantakova
- Amir Maksyutov
- Maria Kuznetsova
- Alexander Khristin
- Natalya Kiryshina
- Vadim Kozlov
- Sergey Sidorov
- Andrey Sokolov
- Alexander Vitsin
- Hiroshi Shiku
- Sergey Sennikov
View Affiliations

Affiliations: Federal State Budgetary Scientific Institution ‘Research Institute of Fundamental and Clinical Immunology’, Novosibirsk 630099, Russian Federation, State Clinical Hospital No. 1, Novosibirsk, Novosibirsk 630075, Russian Federation, Novosibirsk Regional Clinical Oncological Center, Novosibirsk, Novosibirsk 630108, Russian Federation
Published online on: October 3, 2022 https://doi.org/10.3892/mco.2022.2588
Article Number: 155

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dendritic cells (DCs) loaded with tumor‑associated antigens (TAAs) are known to be crucial for the antitumor response and are still included in various treatment regimens in cancer immunotherapy research. In the present study, a cell‑based protocol was evaluated, involving the use of original DNA constructs encoding the wide range of TAA epitopes expressed on different epithelial cancers. The constructs were transfected into in vitro‑generated DCs of patients with various types of cancer, including breast, colorectal and non‑small cell lung cancer. The direct cytotoxicity assay of effector cells, activated with the transfected DCs, revealed a significant increase in cytotoxicity against autologous tumor cells. The use of DNA constructs encoding a large number of TAAs for insertion into DCs in vitro, aiming to activate a T‑cell response may prove to be a reliable and unified approach for immunotherapy and for the prevention of relapse in patients with epithelial cancers.

View Figures

View References

1	Korman AJ, Peggs KS and Allison JP: Checkpoint blockade in cancer immunotherapy. Adv Immunol. 90:297–339. 2006.PubMed/NCBI View Article : Google Scholar
2	Chowdhury PS, Chamoto K and Honjo T: Combination therapy strategies for improving PD-1 blockade efficacy: A new era in cancer immunotherapy. J Intern Med. 283:110–120. 2018.PubMed/NCBI View Article : Google Scholar
3	Ishida Y, Agata Y, Shibahara K and Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895. 1992.PubMed/NCBI View Article : Google Scholar
4	Leach DR, Krummel MF and Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science. 271:1734–1736. 1996.PubMed/NCBI View Article : Google Scholar
5	Shi X, Li CW, Tan LC, Wen SS, Liao T, Zhang Y, Chen TZ, Ma B, Yu PC, Lu ZW, et al: Immune co-inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in medullary thyroid cancers: A large cohort study. J Clin Endocrinol Metab. 106:120–132. 2021.PubMed/NCBI View Article : Google Scholar
6	Ou X, Ma Q, Yin W, Ma X and He Z: CRISPR/Cas9 gene-editing in cancer immunotherapy: Promoting the present revolution in cancer therapy and exploring more. Front Cell Dev Biol. 9(674467)2021.PubMed/NCBI View Article : Google Scholar
7	Pettitt D, Arshad Z, Smith J, Stanic T, Holländer G and Brindley D: CAR-T cells: A systematic review and mixed methods analysis of the clinical trial landscape. Mol Ther. 26:342–353. 2018.PubMed/NCBI View Article : Google Scholar
8	Li S, Zhang Z, Lai WF, Cui L and Zhu X: How to overcome the side effects of tumor immunotherapy. Biomed Pharmacother. 130(110639)2020.PubMed/NCBI View Article : Google Scholar
9	Medler TR, Cotechini T and Coussens LM: Immune response to cancer therapy: Mounting an effective antitumor response and mechanisms of resistance. Trends Cancer. 1:66–75. 2015.PubMed/NCBI View Article : Google Scholar
10	Li Q, Carr AL, Donald EJ, Skitzki JJ, Okuyama R, Stoolman LM and Chang AE: Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern. Cancer Res. 65:1063–1070. 2005.PubMed/NCBI
11	Mortara L, Balza E, Bruno A, Poggi A, Orecchia P and Carnemolla B: Anti-cancer therapies employing IL-2 cytokine tumor targeting: Contribution of innate, adaptive and immunosuppressive cells in the anti-tumor efficacy. Front Immunol. 9(2905)2018.PubMed/NCBI View Article : Google Scholar
12	Dubensky TW Jr and Reed SG: Adjuvants for cancer vaccines. Semun Immunol. 22:155–161. 2010.PubMed/NCBI View Article : Google Scholar : Mantia-Smaldone GM and Chu CS: A review of dendritic cell therapy for cancer: Progress and challenges. BioDrug 27, 453-468, 2013.
13	Higgins JP, Bernstein MB and Hodge JW: Enhancing immune responses to tumor-associated antigens. Cancer Biol Ther 8: 1440-1449, 2009; Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012.PubMed/NCBI View Article : Google Scholar
14	Tang K, Wu YH, Song Y and Yu B: Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy. J Hematol Oncol. 14(68)2021.PubMed/NCBI View Article : Google Scholar
15	Yu B, Kusmartsev S, Cheng F, Paolini M, Nefedova Y, Sotomayor E and Gabrilovich D: Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res. 9:285–294. 2003.PubMed/NCBI
16	Teitz-Tennenbaum S, Li Q, Davis MA, Wilder-Romans K, Hoff J, Li M and Chang AE: Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer. J Immunother. 32:602–612. 2009.PubMed/NCBI View Article : Google Scholar
17	Belderbos RA, Aerts JGJV and Vroman H: Enhancing dendritic cell therapy in solid tumors with immunomodulating conventional treatment. Mol Ther Oncolytics. 13:67–81. 2019.PubMed/NCBI View Article : Google Scholar
18	Kawano M, Tanaka K, Itonaga I, Iwasaki T, Miyazaki M, Ikeda S and Tsumura H: Dendritic cells combined with doxorubicin induces immunogenic cell death and exhibits antitumor effects for osteosarcoma. Oncol Lett. 11:2169–2175. 2016.PubMed/NCBI View Article : Google Scholar
19	Bai R, Chen N, Li L, Du N, Bai L, Lv Z, Tian H and Cui J: Mechanisms of cancer resistance to immunotherapy. Front Oncol. 10(1290)2020.PubMed/NCBI View Article : Google Scholar
20	Santos PM and Butterfield LH: Dendritic cell-based cancer vaccines. J Immunol. 200:443–449. 2018.PubMed/NCBI View Article : Google Scholar
21	Lee C, Lee M and Rhee I: Distinct features of dendritic cell-based immunotherapy as cancer vaccines. Clin Exp Vaccine Res. 7:16–23. 2018.PubMed/NCBI View Article : Google Scholar
22	Giovanelli P, Sandoval TA and Cubillos-Ruiz JR: Dendritic cell metabolism and function in tumors. Trends Immunol. 40:699–718. 2019.PubMed/NCBI View Article : Google Scholar
23	Steinman RM and Nussenzweig MC: Dendritic cells: Features and functions. Immunol Rev. 53:127–147. 1980.PubMed/NCBI View Article : Google Scholar
24	Gardner A, de Mingo Pulido Á and Ruffell B: Dendritic cells and their role in immunotherapy. Front Immunol. 11(924)2020.PubMed/NCBI View Article : Google Scholar
25	Satthaporn S, Robins A, Vassanasiri W, El-Sheemy M, Jibril JA, Clark D, Valerio D and Eremin O: Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother. 53:510–518. 2004.PubMed/NCBI View Article : Google Scholar
26	Gallois A and Bhardwaj N: Dendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironment. Front Immunol. 4(436)2013.PubMed/NCBI View Article : Google Scholar
27	Mastelic-Gavillet B, Sarivalasis A, Lozano LE, Wyss T, Inoges S, de Vries IJM, Dartiguenave F, Jichlinski P, Derrè L, Coukos G, et al: Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer. Eur J Cancer. 135:173–182. 2020.PubMed/NCBI View Article : Google Scholar
28	Bandola-Simon J and Roche PA: Dysfunction of antigen processing and presentation by dendritic cells in cancer. Mol Immunol. 113:31–37. 2019.PubMed/NCBI View Article : Google Scholar
29	Yang L and Carbone DP: Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res. 92:13–27. 2004.PubMed/NCBI View Article : Google Scholar
30	Restifo NP, Dudley ME and Rosenberg SA: Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat Rev Immunol. 12:269–281. 2012.PubMed/NCBI View Article : Google Scholar
31	Shevchenko JA, Khristin AA, Kurilin VV, Kuznetsova MS, Blinova DD, Starostina NM, Sidorov SV and Sennikov SV: Autologous dendritic cells and activated cytotoxic T-cells as combination therapy for breast cancer. Oncol Rep. 43:671–680. 2020.PubMed/NCBI View Article : Google Scholar
32	Ophir E, Bobisse S, Coukos G, Harari A and Kandalaft LE: Personalized approaches to active immunotherapy in cancer. Biochim Biophys Acta. 1865:72–82. 2016.PubMed/NCBI View Article : Google Scholar
33	Sennikov SV, Khantakova JN, Kulikova EV, Obleukhova IA and Shevchenko JA: Modern strategies and capabilities for activation of the immune response against tumor cells. Tumour Biol. 39(1010428317698380)2017.PubMed/NCBI View Article : Google Scholar
34	Brossart P, Schneider A, Dill P, Schammann T, Grünebach F, Wirths S, Kanz L, Bühring HJ and Brugger W: The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 61:6846–6850. 2001.PubMed/NCBI
35	Cloosen S, Arnold J, Thio M, Bos GM, Kyewski B and Germeraad WT: Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: Implications for self-tolerance and tumor therapy. Cancer Res. 67:3919–3926. 2007.PubMed/NCBI View Article : Google Scholar
36	Baeuerle PA and Gires O: .: EpCAM (CD326) finding its role in cancer. Br J Cancer. 96:417–423. 2007.PubMed/NCBI View Article : Google Scholar
37	Criscitiello C: Tumor-associated antigens in breast cancer. Breast Care (Basel). 7:262–266. 2012.PubMed/NCBI View Article : Google Scholar
38	Sennikov SV, Shevchenko JA, Kurilin VV, Khantakova JN, Lopatnikova JA, Gavrilova EV, Maksyutov RA, Bakulina AY, Sidorov SV, Khristin AA and Maksyutov AZ: Induction of an antitumor response using dendritic cells transfected with DNA constructs encoding the HLA-A^*02:01-restricted epitopes of tumor-associated antigens in culture of mononuclear cells of breast cancer patients. Immunol Res. 64:171–180. 2016.PubMed/NCBI View Article : Google Scholar
39	Kuznetsova M, Lopatnikova J, Shevchenko J, Silkov A, Maksyutov A and Sennikov S: Cytotoxic activity and memory T cell subset distribution of in vitro-stimulated CD8+ T cells specific for HER2/neu epitopes. Front Immunol. 10(1017)2019.PubMed/NCBI View Article : Google Scholar
40	Sennikov SV, Maksyutov AZ, Maksyutov RA, Bakulina AY, Gavrilova EV, Kurilin VV, Lopatnikova YA, Shevchenko YA, Obleukhova IA, Kulikova EV, et al: The polyepitope antitumor vaccine construct containing epitopes of tumor-associated antigens, pharmaceutical composition, and its application to elicit the specific antitumor immune response. RF Patent 2684235. Filed November 29, 2016; issued April 4, 2019.
41	Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O and Nielsen M: NetMHC-3.0: Accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 36 (Web Server Issue):W509–W512. 2008.PubMed/NCBI View Article : Google Scholar
42	Antonets DV and Maksiutov AZ: TEpredict: Software for T-cell epitope prediction. Mol Biol. 44:119–127. 2010.PubMed/NCBI
43	Böyum A: Separation of leukocytes from blood and bone marrow. Introduction. Scand J Clin Lab Invest Suppl. 97(7)1968.PubMed/NCBI
44	Rufer N, Brümmendorf TH, Kolvraa S, Bischoff C, Christensen K, Wadsworth L, Schulzer M and Lansdorp PM: Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med. 190:157–167. 1999.PubMed/NCBI View Article : Google Scholar
45	Arrigucci R, Bushkin Y, Radford F, Lakehal K, Vir P, Pine R, Martin D, Sugarman J, Zhao Y, Yap GS, et al: FISH-flow, a protocol for the concurrent detection of mRNA and protein in single cells using fluorescence in situ hybridization and flow cytometry. Nat Protoc. 12:1245–1260. 2017.PubMed/NCBI View Article : Google Scholar
46	Schneider T, Hoffmann H, Dienemann H, Schnabel PA, Enk AH, Ring S and Mahnke K: Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3. J Thorac Oncol. 6:1162–1168. 2011.PubMed/NCBI View Article : Google Scholar
47	Hu Y, Qi W, Sun L, Zhou H, Zhou B and Yang Z: Effect of TGF-β1 on blood CD4+CD25 high regulatory T cell proliferation and Foxp3 expression during non-small cell lung cancer blood metastasis. Exp Ther Med. 16:1403–1410. 2018.PubMed/NCBI View Article : Google Scholar
48	Obleukhova I, Kiryishina N, Falaleeva S, Lopatnikova J, Kurilin V, Kozlov V, Vitsin A, Cherkasov A, Kulikova E and Sennikov S: Use of antigen-primed dendritic cells for inducing antitumor immune responses in vitro in patients with non-small cell lung cancer. Oncol Lett. 15:1297–1306. 2018.PubMed/NCBI View Article : Google Scholar
49	Fiala O, Šorejs O, Šustr J and Fínek J: Side effects and efficacy of immunotherapy. Klin Onkol. 33:8–10. 2020.PubMed/NCBI View Article : Google Scholar
50	Blidner AG, Choi J, Cooksley T, Dougan M, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, et al: Cancer immunotherapy-related adverse events: Causes and challenges. Support Care Cancer. 28:6111–6117. 2020.PubMed/NCBI View Article : Google Scholar
51	Kichloo A, Albosta M, Dahiya D, Guidi JC, Aljadah M, Singh J, Shaka H, Wani F, Kumar A and Lekkala M: Systemic adverse effects and toxicities associated with immunotherapy: A review. World J Clin Oncol. 12:150–163. 2021.PubMed/NCBI View Article : Google Scholar
52	Boudewijns S, Westdorp H, Koornstra RH, Aarntzen EH, Schreibelt G, Creemers JH, Punt CJ, Figdor CG, de Vries IJ, Gerritsen WR and Bol KF: Immune-related adverse events of dendritic cell vaccination correlate with immunologic and clinical outcome in stage III and IV melanoma patients. J Immunother. 39:241–248. 2016.PubMed/NCBI View Article : Google Scholar
53	Chen C, Ma YH, Zhang YT, Zhang F, Zhou N, Wang X, Liu T and Li YM: Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: A systematic review and meta-analysis. Cytotherapy. 20:975–989. 2018.PubMed/NCBI View Article : Google Scholar
54	Mellman I and Steinman RM: Dendritic cells: Specialized and regulated antigen processing machines. Cell. 106:255–258. 2001.PubMed/NCBI View Article : Google Scholar
55	Blankenstein T, Coulie PG, Gilboa E and Jaffee EM: The determinants of tumour immunogenicity. Nat Rev Cancer. 12:307–313. 2012.PubMed/NCBI View Article : Google Scholar
56	Picard E, Verschoor CP, Ma GW and Pawelec G: Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer. Front Immunol. 11(369)2020.PubMed/NCBI View Article : Google Scholar
57	Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, et al: Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19:40–50. 2018.PubMed/NCBI View Article : Google Scholar
58	de Vries NL, Swets M, Vahrmeijer AL, Hokland M and Kuppen PJ: The immunogenicity of colorectal cancer in relation to tumor development and treatment. Int J Mol Sci. 17(1030)2016.PubMed/NCBI View Article : Google Scholar
59	Zhou J, Yu X, Hou L, Zhao J, Zhou F, Chu X, Wu Y, Zhou C and Su C: Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer. Lung Cancer. 153:143–149. 2021.PubMed/NCBI View Article : Google Scholar